Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Name: Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma
Published: 2012
License: Public Domain

Alliance for Clinical Trials in Oncology · 2012

ClinicalTrials.gov · Datasets · License: Public Domain · 2012

Open Source ↗

refractory/relapsed indolent non-hodgkin lymphoma, recurrent grade 1 follicular lymphoma, recurrent grade 2 follicular lymphoma, recurrent marginal zone lymphoma, recurrent small lymphocytic lymphoma, extranodal marginal zone b-cell lymphoma of mucosa-associated lymphoid tissue, waldenström macroglobulinemia, nodal marginal zone b-cell lymphoma, splenic marginal zone lymphoma, interventional, phase1

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Refractory or Relapsed Indolent Non-Hodgkin Lymphoma

Related documents